76 results
8-K
EX-1.1
TRML
Tourmaline Bio Inc
26 Jan 24
Other Events
4:12pm
and expenses of the nature referred to in Item 14 of Part II of the Registration Statement. Except as provided in this Section 4 or in Section 7
424B5
TRML
Tourmaline Bio Inc
26 Jan 24
Prospectus supplement for primary offering
4:08pm
that are not strictly historical in nature are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended
424B5
TRML
Tourmaline Bio Inc
24 Jan 24
Prospectus supplement for primary offering
9:20pm
that are not strictly historical in nature are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended
8-K
EX-99.1
ri97a759d7o
24 Jan 24
Results of Operations and Financial Condition
5:10pm
8-K
EX-99.3
x81xih3bffx x2cq
24 Jan 24
Results of Operations and Financial Condition
5:10pm
8-K
EX-99.2
uqn iew8548hzkp
24 Jan 24
Results of Operations and Financial Condition
5:10pm
8-K
EX-99.1
ceyp0
14 Nov 23
Index to Unaudited Condensed Financial Statements
5:15pm
8-K
EX-10.7
01ntxa5 fzcuinn3
19 Oct 23
Tourmaline Bio Announces Closing of Merger with Talaris Therapeutics and Concurrent Private Placement of $75 Million
9:11pm
8-K
EX-10.10
k6g5peua 81lqdrk1
19 Oct 23
Tourmaline Bio Announces Closing of Merger with Talaris Therapeutics and Concurrent Private Placement of $75 Million
9:11pm
8-K
EX-10.9
y8x0xc86k383j
19 Oct 23
Tourmaline Bio Announces Closing of Merger with Talaris Therapeutics and Concurrent Private Placement of $75 Million
9:11pm
425
hs8fkex
10 Oct 23
Business combination disclosure
4:32pm
8-K/A
xgx6v9
10 Oct 23
Other Events
4:30pm
425
5a63l57qtc89t0avu
6 Oct 23
Business combination disclosure
5:27pm
8-K
gf9hr9tnm
6 Oct 23
Other Events
5:26pm
425
ernpwvaikroo
26 Sep 23
Business combination disclosure
8:24am
8-K
EX-99.1
8qubi5wah2a i91tc3jb
26 Sep 23
Regulation FD Disclosure
8:21am
8-K
bgjbw
26 Sep 23
Regulation FD Disclosure
8:21am